Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0JZQWX
ADC Name
huAb3v2.5-SR
Synonyms
huAb3v2.5 SR; huAb3v2.5SR
   Click to Show/Hide
Organization
AbbVie, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Small cell lung cancer [ICD11:2C25]
Investigative
Drug-to-Antibody Ratio
1.8
Structure
Antibody Name
huAb3v2.5
  Antibody Info 
Antigen Name
CD276 antigen (CD276)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
huAb3v2.5-SR linker
Combination Type
AbbVie's SR
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
0.59
nM
NCI-H1650 cells
Lung adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.59 nM Positive CD276 expression (CD276 +++/++)
Method Description
The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model Lung adenocarcinoma NCI-H1650 cells CVCL_1483
References
Ref 1 Anti-b7-h3 antibodies and antibody drug conjugates; 2018-03-08.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.